1. Home
  2. CTSO vs AIXI Comparison

CTSO vs AIXI Comparison

Compare CTSO & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • AIXI
  • Stock Information
  • Founded
  • CTSO 1997
  • AIXI 2001
  • Country
  • CTSO United States
  • AIXI China
  • Employees
  • CTSO N/A
  • AIXI N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • AIXI Computer Software: Prepackaged Software
  • Sector
  • CTSO Health Care
  • AIXI Technology
  • Exchange
  • CTSO Nasdaq
  • AIXI Nasdaq
  • Market Cap
  • CTSO 51.6M
  • AIXI 54.2M
  • IPO Year
  • CTSO N/A
  • AIXI 2023
  • Fundamental
  • Price
  • CTSO $1.15
  • AIXI $5.30
  • Analyst Decision
  • CTSO Strong Buy
  • AIXI
  • Analyst Count
  • CTSO 3
  • AIXI 0
  • Target Price
  • CTSO $4.67
  • AIXI N/A
  • AVG Volume (30 Days)
  • CTSO 147.4K
  • AIXI 192.2K
  • Earning Date
  • CTSO 03-06-2025
  • AIXI 10-28-2024
  • Dividend Yield
  • CTSO N/A
  • AIXI N/A
  • EPS Growth
  • CTSO N/A
  • AIXI N/A
  • EPS
  • CTSO N/A
  • AIXI N/A
  • Revenue
  • CTSO $37,739,531.00
  • AIXI $65,643,604.00
  • Revenue This Year
  • CTSO $9.20
  • AIXI $22.85
  • Revenue Next Year
  • CTSO $11.64
  • AIXI $22.70
  • P/E Ratio
  • CTSO N/A
  • AIXI N/A
  • Revenue Growth
  • CTSO 1.80
  • AIXI 6.22
  • 52 Week Low
  • CTSO $0.70
  • AIXI $2.06
  • 52 Week High
  • CTSO $1.61
  • AIXI $22.05
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 55.74
  • AIXI 53.73
  • Support Level
  • CTSO $1.06
  • AIXI $4.85
  • Resistance Level
  • CTSO $1.61
  • AIXI $5.43
  • Average True Range (ATR)
  • CTSO 0.13
  • AIXI 0.45
  • MACD
  • CTSO 0.01
  • AIXI 0.06
  • Stochastic Oscillator
  • CTSO 29.34
  • AIXI 83.71

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: